CING | Cingulate Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.92 - 5.48
52 Week Range	1.8000 - 187.20
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	405,525
Average Volume	3,985,002
Shares Outstanding	2,179,755
Market Cap	10,789,787
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-12-08

Valuation
Profitability
Growth
Health
P/E Ratio	-0.02
Forward P/E Ratio	N/A
EPS	-326.40
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	CING

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CING's peers: BRTX, CANF, SABSW, SNTI, BLCM, HILS, AVTE, ADAG, ACRV, RZLT, ANTX, GNLX, CMRA, DYAI, MNPR, MIRO, IKT, PMVP, ANEB, EDSA, NRXP, PPBT, MAIA, CINGW, IMNN

*Chart delayed

Analyzing fundamentals for CING we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CING Fundamentals page.

Watching at CING technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CING Technicals page.